Facebook
X
LinkedIn
ForwardJohn Slevin, MD, MBA
Dr. Slevin graduated from West Virginia University College of Medicine, completed neurology residency at the University of Virginia, and fellowship trained in neuropharmacology at Johns Hopkins Medical Institutions.
He is the Vice Chair of Research for the Department of Neurology, director of the Movement Disorders group in the Department and Director of the Braden-Clark Movement Disorders Fellowship.
His clinical interests include Movement Disorders, Parkinson’s disease, and deep brain stimulation.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:NeuroDerm, LtdTopic:Multicenter, Randomized, Active-controlled, Double-bind, Double-dummy, Parallel Group Clinical Trial on Parkinson's diseaseDate added:08/07/2026Date updated:08/08/2026Relationship end date:12/31/2026
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Intrance Medical Systems, IncTopic:Pharmacokinetic Study of Lecigon® Enteral Suspension in Subjects with Advanced Parkinson’s DiseaseDate added:08/08/2026Date updated:08/08/2026Relationship end date:12/31/2026
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Neuron 23Topic:Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NEU-411 in early Parkinson's diseaseDate added:08/08/2026Date updated:08/08/2026Relationship end date:12/31/2027
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Sumitomo Pharma AmericaTopic:Multicenter, Sham-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Clinical Responses following Stereotactic Intracranial Implantation of DSP-1083 into Subjects with Parkinson’s DiseaseDate added:08/08/2026Date updated:08/08/2026Relationship end date:12/31/2029
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Cerevance Beta, IncTopic:Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson’s Disease Patients with Motor ComplicationsDate added:08/08/2026Date updated:08/08/2026Relationship end date:12/30/2026
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Appello PharmaceuticalsTopic:Phase 2, Double-Blind, Placebo-Controlled Study To Evaluate The Effectiveness Of Two Doses Of AP-472 As Adjunctive Therapy To Levodopa In Parkinson’s Disease Participants With Motor FluctuationsDate added:08/08/2026Date updated:08/08/2026Relationship end date:12/30/2027
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Novartis Pharma AGTopic:A Phase III, Randomized, Placebo-Controlled, Parallel Group, Double-Blind Study To Evaluate The Efficacy And Safety Of NIO752 In Participants With Progressive Supranuclear PalsyDate added:08/08/2026Date updated:08/08/2026Relationship end date:07/01/2029